Oncopeptides

Interim / Quarterly Report • Aug 21, 2025

INTERIM REPORT, Q2 2025

Third consecutive quarter over quarter double-digit sales growth, 135 percent year over year

APRIL-JUNE

• New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients.
• Oncopeptides launches new Real-World Evidence study of Pepaxti in Spain, first patient enrolled.
• U.S. Food and Drug Administration removes clinical hold of OPD5.

Significant events Financial overview

APRIL-JUNE

• Net sales amounted to SEK 19.2 (8.2) million
• Operating profit amounted to SEK -56.2 (- 73.3) million
• Profit after tax amounted to SEK -62.8 (-73.2) million
• Earnings per share, before and after dilution -0.30 (-0.48) SEK
• Cash and cash equivalents at the end of the period amounted to SEK 70.1 (383.3) million

Events after the period

• Oncopeptides' drug Pepaxti included in European Guidelines for the treatment of multiple myeloma.
• Oncopeptides announces acceptance of poster presentations of Spanish and Italian Real-World data at IMS Annual Meeting.
• Oncopeptides Partners with SD Pharma to further broaden Pepaxti's reach in Spain.
• Oncopeptides announces rights issue.

Selected Key Indicators

	2025	2024	2025	2024	2024
(SEK thousand)	apr-jun	apr-jun	lan-jun	jan-jun	lan-dec
Net sales	19 183	8 155	32 449	13 227	31648
Operating profit	-56 234	-73 251	680 911-	-138 912	-283 498
Profit after tax	-62 849	-73 243	-123 518	-140 948	-284 607
Earnings per share before and after dilution (SEK)	-0.30	-0.48	-0.58	-1.16	-1.71
Cash flow from operating activities	-54 411	8 774	-122 728	-58 587	-260 570
Cash at the end of the period	70 146	383 275	70 146	383 275	178 536

1

CEO Statement

The second quarter of 2025 marks yet another strong step forward for Oncopeptides, with net sales, as previously announced, amounting to SEK 19.2 million – an increase of 45 percent compared to the first quarter, 135 percent versus the same period last year, and 145 percent for the first half of the year compared to the same period in 2024. This is our third consecutive quarter of more than 30 percent quarter-on-quarter sales growth. The results reflect robust organic growth in our largest market, Germany, combined with faster-than-expected market access in both Spain and Italy. With July sales also confirming our strong topline momentum with tripled sales compared to the same month last year, we remain confident we are on track to profitability by the end of 2026.

In Germany, targeted commercial and medical activities have driven an acceleration in demand, making a significant contribution to overall growth. In Spain, uptake has been supported by swift regional access which we will work to strengthen in H2 through our recently announced partnership with SD Pharma, which will broaden Pepaxti's reach to additional hospitals and regions without increasing our cost base. Italy has exceeded our early expectations, with the majority of regions already unlocked at hospital level and positive momentum into the third quarter.

In July, Pepaxti was recommended in the updated European Hematology Association–European Myeloma Network guidelines. It was also recognized as an option for patients relapsing after CAR-T or ADC therapy, underscoring the drug's differentiated value in advanced disease. This endorsement from leading experts is

expected to further support physician awareness and adoption across Europe.

We also continue to see growing interest in Pepaxti from the real-world clinical community. In April, new realworld data from the University of Catania reinforced Pepaxti's effectiveness and tolerability in heavily pretreated patients, including those with high-risk features. In July, we announced that real-world evidence from centers in Spain and Italy will be presented at the upcoming International Myeloma Society Annual Meeting in September, adding to the growing body of independent research reflecting positive experiences with Pepaxti in clinical practice.

While we remain fully focused on driving growth in our key European markets, we continue to pursue opportunities to expand Pepaxti's

reach globally. Most importantly, our partnership discussions in Japan are progressing, and we are currently in advanced discussions with one highly reputable partner, with the due diligence process at a late stage, based on a non-binding offer which is in line with market practice and which includes several significant upfront and milestone payments and a doubledigit royalty, with the partner assuming all costs related to regulatory activities and commercialization in Japan. Additionally, we have also received a non-binding offer from another potential partner which we are considering in parallel.

To ensure we have the financial flexibility to sustain our growth trajectory to reach positive cash flow by end of 2026 and progress our pipeline, we have now announced that we are launching a rights issue of up to SEK 150 million. The proceeds will primarily support our ongoing

commercialization in Europe.

With three consecutive quarters of strong double-digit growth, accelerated market access, increasing clinical endorsement, and a strengthened financial foundation, we are entering the second half of the year with confidence. We will continue to execute with commercial and financial discipline, advance our partnerships, and leverage both clinical and real-world evidence to reinforce Pepaxti's position as an important treatment option for patients with advanced multiple myeloma.

Stockholm, August 21, 2025

Sofia Heigis CEO

2

Financial Overview

REVENUE

Net sales of Pepaxti during the quarter were SEK 19.2 (8.2) million and for the six -month period SEK 32.5 (13.2) million. The turnover for the period refers to Europe only.

GROSS PROFIT

Gross profit during the quarter were SEK 18.8 (7.2) million and for the six -month period SEK 32.1 (12.0) million.

OPERATING EXPENSES

Operating expenses during the quarter were SEK 75.0 (80.5) million and for the six -month period SEK 148.2 (151.0) million.

RESEARCH AND DEVELOPMENT EXPENSES

Research and development costs during the quarter were SEK 21.0 (27.9) million and for the six -month period SEK 49.8 (56.1) million. No clinical studies are currently ongoing.

MARKETING AND SALES EXPENSES

Marketing and sales costs during the quarter were SEK 36.6 (36.2) million and for the six month period SEK 65.1 (63.9) million. The slight increased costs relate to ongoing commercialization activities in Europe, focusing on Germany, Spain and Italy.

GENERAL AND ADMINISTRATIVE EXPENSES

Administrative costs during the quarter were SEK 18.6 (16.4) million and for the six -month period SEK 35.4 (34.4) million. Part of the increase in the second quarter is cost associated with exploring optimal financing opportunities.

EXPENSES FOR SHARE BASED INCENTIVE PROGRAMS

For the six -month period, costs, including social security contributions, for share related incentive programs amounted to SEK 2.4 (4.0) million. The cost does not affect cash flow in the period. See note 8.

TAX AND EARNINGS

Profit during the quarter were SEK -62.8 ( - 73.2) million and for the six -month period SEK -123.5 ( -140.9) million. This corresponds to earnings per share for the quarter of SEK 0.30 ( -0.48) and for the six -month period SEK -0.58 ( -1.16).

CASH FLOW, INVESTMENTS AND FINANCIAL POSITION

Cash flow from operating activities amounted to SEK -54.4 (8.8) million. Last year quarter's cash flow was positively affected by SEK 105 million regarding an internal sale of patents whose VAT was regulated in the subsidiary in June and in the parent company in July. The corresponding negative effect of SEK 105 million thus occurred in the third quarter 2024 .

The company has during the quarter used a short -term credit facility amounting to SEK 20 million.

Oncopeptides has loan agreement with the European Investment Bank (EIB). The agreement provides Oncopeptides with access to a loan facility of up to EUR 30 million without collateral. The loan agreement is divided into three parts, tranches, each with a maturity of 5 years, which will be available if the company meets certain conditions. In the second quarter of 2023, Oncopeptides used tranche A of this loan facility, which provided the company with EUR 10 million in cash. As of the reporting date, the company does not fully meet an equity condition meaning that tranche B and C are currently not available.

Equity in the group amounted to SEK -66.9 (193.0) million at the end of the period. Equity for the parent company amounted to SEK 386.9 (699.5) million.

GOING CONCERN

-

The financial statements have been prepared on the assumption that the company has the ability to continue operations for the coming 12 -month period, in line with the going concern principle. The board has decided on a rights issue that is guaranteed with such an amount that it will obtain additional liquidity for the coming 12 -month period and beyond until the company is cash flow positive towards the end of 2026 .

RIGHTS ISSUE 2025

On August 21st the company announced that the Board of Directors has resolved to carry out a guaranteed (up to SEK 130 million) new share issue of approximately SEK 150 million with preferential rights for the Company's existing ordinary shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025, supported by the company's main shareholder and management. The purpose of the Rights Issue is primarily to finance the ongoing commercialization of Pepaxti ® in Europe until the Company expects to become cash flow positive by the end of 2026, and also the progression of the Company's portfolio of pre -clinical assets.

EMPLOYEES

At the end of the quarter, the number of employees amounted to 75 (67).

PARENT COMPANY

The operations of the parent company correspond in all essential respects with the operations of the group, which is why the comments for the group also apply to the parent company.

ONCOPEPTIDES SHARE

At the end of the period, the number of registered shares eligible for trading and votes in Oncopeptides amounted to 225,758,823, inclusive of 14,494,920 C shares held by the company.

AUDITOR REVIEW

This report has not been reviewed by the company's auditors.

Signatures

The Board and the CEO confirm that the interim report provides a true and fair reflection of the Group's and the Parent Company's operations, position and earnings and describes the material risks and uncertainty factors faced by the Parent Company and the companies within the Group.

Stockholm, August 21, 2025

Per Wold -Olsen Sofia Heigis Chairman CEO

Christine Rankin Board member

Per Samuelsson Board member

Brian Stuglik Board member

Condensed consolidated statement of comprehensive income

		2025	2024	2025	2024	2024
SEK thousand	Note	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Net sales	ട്	19 183	8 155	32 449	13 227	31648
Cost of Goods Sold		-395	-947	-310	-1234	-2 663
Gross profit		18 788	7 208	32 139	11 993	28 985
Research and development expenses		-21047	-27 860	-49 774	-56 104	-121186
Marketing and distribution expenses		-36 593	-36 185	-65 081	-63 a02	-136 439
Administrative expenses		-18 630	-16 428	-35 441	-34 372	-60 843
Other operating incomerespenses		1248	14	680 2	3 473	5 985
Total operating expense		-75 022	-80 460	-148 208	-150 905	-312 483
EBIT; Operating profitiloss		-56 234	-73 251	-116 069	-138 912	-283 498
Net financial items		899 8-	29	-7 355	-2 061	-712
EBT; Earnings before tazes		-62 801	-73 222	-123 424	-140 973	-284 209
noome tax		-48	-22	-94	25	-398
Net profit		-62 849	-73 243	-123 518	-140 948	-284 607
Other comprehensive income
Items to be reclassified as profit or loss
Translation variances		169	57	-179	-169	-644
Other comprehensive income after taz		169	57	-179	-169	-644
Total comprehensive income attributable to Parent Company's shareholders.		-62 680	-73 187	-123 696	-141 118	-285 251
Earnings per share beforelafter dilution (SEK)		-0.30	-0.48	-0.58	-1.16	-1.71

Note	2025-06-30	2024-06-30 2024-12-31
	22 343	32 353	27 111
	22 343	32 353	27 111
	7 095	4 790	4 371
	36 857	32 505	34 174
	70 146	383 275	178 536
	114 098	420 569	217 081
	136 441	452 922	244 192
	-66 876	192 963	54 285
	-66 876	192 963	54 285
6	124 230	114 887	121894
	12 785	24 106	16 658
	137 015	138 993	138 552
	8998 Z	8 802	18 171
	58 635	112 164	33 185
	66 303	120 acce	51 355

Condensed consolidated statement of financial position

	2025	2024	2025	2024	2024
SEK Thousand	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Opening balance	-5 843	-8 428	54 285	56 780	56 780
Net profit	-62 849	-73 243	-123 518	-140 948	-284 607
Other comprehensive income	169	57	-179	-169	-644
Total comprehensive income	-62 680	-73 187	-123 696	-141 118	-285 251
Transaction with owners
New issue of shares	0	313 483	1175	313 483	313 483
Repurchase of shares	0		-1175		-
Cost related to share issue	0	-41639	0	-41639	-41639
Share based compensation	0	2 735	0	5 458	10 913
Exercised warrants	1647		2 535		0
Total transactions with owners	1 647	274 578	2 535	277 301	282 756
Ending balance	-66 876	192 963	-66 876	192 963	54 285

	2025	2024	2025	2024	2024
SEK Thousand	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Operating activities
Operating profitiloss	-56 234	-73 251	-116 069	-138 912	-283 498
Adjustment for non-cash items	6 179	4 380	-3 023	9 503	18 620
nterest received	4	5	15	6	6 403
nterest paid	0	3	0	-4	-4
Taxes paid received	40	-125	0	-143	588
Cash-flow from operating activities before
change in working capital	-50 011	-68 994	-119 077	-129 550	-257 891
Change in working capital	-4 400	77 768	-3 651	70 963	-2 679
Cash-flow from operating activities	-54 411	8 774	-122 728	-58 587	-260 570
Cash-flow from investment activities		0	0	0	496
Cash-flow from financing activities	17 961	269 837	15 922	267 830	263 814
Cash-flow for the period	-36 450	278 612	-106 806	209 243	3 740
Cash at the beginning of the period	107 225	104 825	178 536	173 408	173 406
Change in cash	-36 450	278 611	-106 806	209 242	3 740
Effect of exchange rate changes on cash	-630	-160	-1585	626	13889
Cash at the end of the period	70 146	383 276	70 146	383 276	178 536

Condensed Parent Company income statement Condensed Parent Company balance sheet

		2025	2024	2025	2024	2024
(SEK thousand)	Note	apr-jun	apr-jun	apr-jun	jan-jun	jan-dec
Net sales	5	19 183	8 155	32 449	13 227	31648
Cost of Goods Sold		-395	-947	-310	-1234	-2 663
Gross profit		18 788	7 208	32 139	11 993	28 985
Research and development expenses		-24 886	-28 484	-56 450	-56 796	-125 954
Marketing and distribution expenses		-37 701	-34 309	-67 042	-61971	-140 279
Administrative expenses		-18 674	-16 468	-35 527	-34 457	-60 983
Other operating incomerespenses		2 300	424 523	6755	510 242	520 564
Total operating expense		-78 960	345 261	-152 263	357 018	193 349
EBIT; Operating profitiloss		-60 172	352 469	-120 124	369 011	222 334
Net financial items		-935	1 918	4 547	-3	5 898
Earnings after net financial items		-61 108	354 387	-115 577	369 007	228 232
Group contribution		-12 047	-5 014	-27 552	-7 031	-43 Bala
EBT; Earnings before tazes		-73 154	349 373	-143 129	361 977	184 577
1 ax		0	0	0	0	0
Net profit		-73 154	349 373	-143 129	361 977	184 577

Condensed Parent Company statement of comprehensive income

	2025	2024	2025	2024	2024
SEK thousand	apr-jun	apr-jun	apr-jun	jan-jun	jan-dec
EBT; Earnings before taxes	-73 154	349 373	-143 129	361977	184 577
Other comprehensive income
Net profits		-73 154 349 373	-143 129	361 977	184 577

SEK thousand	Note	2025-06-30	2024-06-30	2024-12-31
Assets
Tangible assets		4 809	6 341	C 053
Financial assets		500 445	501297	500 445
Total non-current assets		505 254	508 239	506 498
Current assets
Inventory		7 095	4 790	4 371
Current receivables		880 96	17 450	108 220
Cash		62 100	339 533	141143
Total current assets		165 284	361 773	253 734
Total assets		670 538	870 012	760 233
Equity and liabilities
Restricted equity		35 293	34 118	34 118
Non-restricted capital		351 616	665 328	493 383
Total Equity		606 988	699 447	527 502
Long term liabilities
Loans from credit institutions	6	124 230	114 887	121894
Long-term liabilities		3 931	8 001	4 110
Total long-term liabilities		128 161	122 888	126 004
Current liabilities
Trade payables		6 179	7 181	15 318
Other current liabilities		149 289	40 496	91 409
Total current liabilities		155 468	47 678	106 7277
Total equity and liabilities		670 538	870 012	760 233

NOTE 1 - GENERAL INFORMATION

This interim report covers the Swedish parent company Oncopeptides AB (publ), registration number 556596-6438, as well as the wholly owned subsidiaries Oncopeptides Incentive AB, Oncopeptides Innovation AB (with the wholly owned subsidiary Oncopeptides Innovation 1 AB), Oncopeptides GmbH and Oncopeptides Srl and Oncopeptides SL. The parent company is a public limited company based in Stockholm. The figures in brackets in the report refer to the corresponding period of the previous year. The interim report has been approved for publication on 21 August 2025.

NOTE 2 - ACCOUNTING PRINCIPLES

The group's interim report is prepared in accordance with IAS 34. The parent company applies the Swedish Financial Reporting Council's recommendation RFR 2. Oncopeptides applies, other than what appears below, the same accounting principles as in the most recent annual report. Significant accounting and valuation principles can be found on pages 43-48 of the annual report for 2024. No new or changed standards have been introduced since 1 January 2025 that have had any significant impact on the company's financial reporting.

Oncopeptides applies ESMA's (European Securities and Markets Authority) guidelines for alternative key figures.

NOTE 3 - RISKS AND UNCERTAINTIES

In its operations, Oncopeptides is exposed to a number of risks. The company continuously evaluates known and predictable risks and acts to minimize the effect of these risks within the framework of the company's business strategy and safeguarding the company's long-term interests, including its sustainability. The company assesses that the risks described in the annual report for 2024 remain during the period.

NOTE 4 - ESTIMATES AND CONSIDERATIONS

This report contains forward-looking statements. Actual results may differ from those stated. Internal factors such as successful management of research programs and intellectual property rights may affect future results. The interim report has been prepared with the assumption that the company has the ability to continue operations during the next 12-month period, in line with the going concern principle.

NOTE 5 - REVENUE RECOGNITION

There has been no change in the principle of revenue recognition compared to the annual report 2024. Revenue is recognized at the transaction price for goods sold excluding value added tax, discounts and returns. Revenue is recognized at the time of delivery when Oncopeptides has fulfilled its performance commitment and control of the goods passes to the customer.

The customers are defined as hospitals and/or clinics and retailers who sell the goods to the final user of the goods. As the final price is related to the discount that applies in the respective local market the parent company and the group report a liability for a calculated discount based on the frameworks for discounts that apply in each market. The provision for estimated discounts is reported under the heading Other short-term liabilities in the balance sheet.

Group revenue	2025	2024	2025	2024	2024
SEK thousand	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Net sales
Goods	19 183	8 155	32 449	13 227	30 517
Milestone South Korea	0	0	0	0	1131
Reversal of return reserve	0	0	0		0
Total net revenue	19 183	8 155	32 449	13 227	31 648
Geographical market
USA	0		0		0
Europe	19 183	8 155	32 449	13 227	30 517
Asia	0		0	0	1131
Total net revenue	19 183	8 155	32 449	13 227	31 648

NOTE 6 – LOANS FROM CREDIT INSTITUTIONS

The liability relate to a loan from EIB. It will not be amortized until the 16th of June 2028, when it will be fully repaid. The interest is accumulated and capitalized during the term and paid in connection to the repayment of the loan. The contractual interest rate is 7% for the full term. The effective interest rate is estimated to 10.8%, including arrangement costs and the initial market value of the transferred

warrants allocated during the term of the loan.

In connection to the signing of the agreement, an issue of 2 829 231 warrants was performed, whereof 1 138 646 warrants representing 1.26% of outstanding shares after dilution has been transferred to EIB without compensation. The remaining warrants are held by the company and may be transferred to EIB in connection to a possible utilization of the remaining tranches related to the loan agreement.

EIB has the right to exercise the warrants and subscribe for shares at the quota value. The warrants may be exercised at any time for a period of 20 years, in full or in part, by the warrant holder.

EIB has the right, under certain circumstances and in connection to the repayment of the loan, to demand that Oncopeptides acquire the warrants at fair value in a situation when it is not possible to transfer the warrants to a third party.

NOTE 7 - RELATED PARTY TRANSACTIONS

Remuneration to senior management has been paid in accordance with current policies. No other transactions with related parties, outside of the Oncopeptides Group, occurred during the period.

NOTE 8 - SHARE BASED INCENTIVE PROGRAMS

The purpose of share -based incentive programs is to promote the company's long -term interests by motivating and rewarding the company's senior management, founders, and other co -workers in line with the interest of the shareholders. Oncopeptides has currently nine programs that include the management team, certain Board members, founders and employees.

Program

• 2017; "Co -worker LTIP 2017"
• 2018; "Co -worker LTIP 2018"
• 2019; "Co -worker LTIP 2019"
• 2021; "Co -worker LTIP 2021"
• 2022; "Co -worker LTIP 2022" and "Board SHP 2022"
• 2023; " Co -worker LTIP 2023"
• 2024; " Co -worker LTIP 2024" and "Board SHP 2024"

For more information on the programs see Note 26 in the Annual report 2024 as well as Agendas and Minutes from the relevant Annual General Meetings on the company's website www.oncopeptides.com.

At the end of the period, full utilization (including warrants for securing social security contributions but excluding warrants related to EIB), of

• Options and share awards resolved by the AGM and awarded to named individuals corresponding to 10,109,772 shares, would result in a dilution of 4.6 percent.
• Options and share awards resolved by the AGM and awarded to named individuals as well as those not yet awarded to individuals, corresponding to 17,704,225 shares, would result in a dilution of 7.7 percent.

NOTE 9 - SIGNIFICANT EVENTS AFTER THE PERIOD

No significant events occurred after the end of the period other than as mentioned in the report.

Key performance measures

In this report, certain key performance measures are presented, including measures that are not defined under IFRS, • Research and development /

operating expenses, %, • Gross margin, TSEK, %. The company believes that these measurements provides valuable additional information when

evaluating the company's economic trends. These financial performance measures should not be viewed in isolation, nor be considered in replacement of performance indicators that are prepared in accordance with IFRS.

Further, such performance measures, as the company has defined them, should not be compared with other performance measures with similar names used by other companies since definitions and calculation methods may vary between companies.

	2025	2024	2025	2024	2024
SEK. Thousand	apr-jun	apr-jun	jan-jun	jan-jun	jan-dec
Net sales	19 183	8 155	32 449	13 227	31648
Gross profit11	18 788	7 208	32 139	11 993	28 985
Gross margin21	98%	88%	766	91%	92%
Registered common shares outstanding
beginning of period	211 263 903	90 439 627	211 263 903	90 439 627	90 439 627
end of period	211 263 903	211 263 903	211 263 903	211 263 903	211 263 903
C-shares for LTI programs31	14 494 920	3 922 343	14 494 920	3 922 343	3 922 343
Registered shares; end of period including C-shares	225 758 823	215 186 246	225 758 823	215 186 246	215 186 246
Share capital at the end of period	23 910	23 910	23 910	23 910	23 910
Equity at the end of period	-66 876	192 363	-66 876	192 963	54 285
Earnings per share beforelafter dilution, kr41	-0,30	-0.48	-0,58	-1.16	-1.71
Operating loss	-56 234	-73 251	690 911-	-138 912	-283 498
Research and development expenses	-21047	-27 860	-49 774	-56 104	-121 186
R&D coststoperating expenses, %51	28%	35%	34%	37%	39%

1) Defined by subtracting cost of goods sold from total sales. The key figure shows gross profitability of cost of goods sold in absolute numbers.

2) Defined by dividing the sum of the company's gross profit by total sales. The key figure aims to clarify the relative profitability of goods sold.

3) For more information, please see the notice to the Annual General Meeting 2024.

4) Earnings per share before dilution are calculated by dividing earnings attributable to shareholders of the Parent Company by a weighted average number of outstanding shares during the period. There is no dilution effect driven by the employee stock option program, as earnings for the periods have been negative.

5) Defined by dividing the research and development costs with total operating expenses. The key performance measure provides an indication of the proportion of expenses that are attributable to the company's core business.

Telephone conference

The interim report for the period and an operational update will be presented by CEO Sofia Heigis and members of Oncopeptides Leadership team, Thursday August 21, 2025, at 09:00 (CET).

If you wish to participate via webcast, please use the link below. Through the webcast you can ask written questions. https://oncopeptides.events.inderes.c om/q2-report-2025

If you wish to participate via telephone conference, please register on the link below. After registration you will be provided a phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. https://conference.inderes.com/teleco nference/?id=5005747

Report	Date
Interim report Q3 2025	5 November 2025
Year-end report 2025	19 February 2026

Contact

Oncopeptides AB

Financial Calendar

Kontakt Visiting address; Luntmakargatan 46, 111 37 Stockholm Domicile: Luntmakargatan 46, 111 37 Stockholm, Sweden

Telephone: +46 8 615 20 40 E-mail: info@oncopeptides.com

Website: oncopeptides.com

Thesaurus

Thesaurus EMA European Medicines Agency Europeiska läkemedelsmyndigheten

CHMP The European Medicines Agency's Committee for Medicinal Products for Human Use Europeiska läkemedelsmyndighetens kommitté för humanläkemedel